STOCK TITAN

Acer Therapeutics Inc. - $ACER STOCK NEWS

Welcome to our dedicated page for Acer Therapeutics news (Ticker: $ACER), a resource for investors and traders seeking the latest updates and insights on Acer Therapeutics stock.

Acer Therapeutics Inc. (Nasdaq: ACER), based in Cambridge, MA, is a pioneering biotechnology company focused on developing repurposed and reformulated medicines to address ultra-orphan diseases with significant unmet medical needs. Acer's flagship product, OLPRUVA™ (sodium phenylbutyrate), was approved by the FDA in December 2022 and targets urea cycle disorders (UCDs), conditions that prevent the body from removing waste nitrogen, leading to serious health issues. OLPRUVA™ is now available in all dosage strengths and is supported by a dedicated patient support team through Navigator by Acer Therapeutics to ensure seamless prescription management and patient care.

In addition to OLPRUVA™, Acer is also developing EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS) and has paused the development of ACER-801 (osanetant) for Vasomotor Symptoms (VMS) and other conditions. The company is actively engaged in discussions with major pharmacy benefits managers and government payers to secure insurance coverage for OLPRUVA™, which is expected to be included in commercial insurance plans by the second half of 2023 and Medicaid programs by the third quarter of 2023.

Acer has recently regained worldwide rights to OLPRUVA™ (excluding Geographical Europe) from Relief Therapeutics, allowing the company to reinvest more capital into potential lifecycle expansion opportunities. This move aims to maximize the global commercialization of OLPRUVA™, ensuring it reaches as many patients in need as possible.

The company's strategic focus on rare diseases underscores its commitment to transforming the lives of patients with limited treatment options, leveraging innovative solutions like OLPRUVA™ to address critical health challenges globally.

Rhea-AI Summary
Acer Therapeutics reacquires worldwide rights to OLPRUVA from Relief Therapeutics, excluding Geographical Europe. Relief receives upfront payment of $10 million and potential total payments of up to $56.5 million. Acer regains economic rights without profit sharing and plans to reinvest in potential expansion opportunities. Relief retains development and commercialization rights in Geographical Europe. OLPRUVA now available in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
109.84%
Tags
-
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) has made OLPRUVA™ (sodium phenylbutyrate) kits available in all dosage strengths and ready to ship to patients. The company reported financial results for the second quarter ended June 30, 2023, with a cash position of $1.6 million. Acer anticipates attaining OLPRUVA™ commercial insurance coverage and Medicaid patient insurance coverage in Q3 2023. They also expect to complete enrollment in their pivotal Phase 3 DiSCOVER trial of EDSIVO™ in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
-
Rhea-AI Summary
Acer Therapeutics provides an update on the commercial launch of OLPRUVA™, a treatment for certain UCD patients. The drug availability is now expected in mid-June 2023, ahead of schedule. Acer has also made progress in discussions with payers for reimbursement and has seen increased physician interest in using OLPRUVA™. The company expects to begin accepting prescriptions in mid-June 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.77%
Tags

FAQ

What is Acer Therapeutics Inc.?

Acer Therapeutics Inc. is a biotech company focused on developing repurposed and reformulated medicines for ultra-orphan diseases with significant unmet medical needs.

What is OLPRUVA™?

OLPRUVA™ (sodium phenylbutyrate) is a prescription medicine approved by the FDA for the treatment of urea cycle disorders (UCDs).

What are urea cycle disorders (UCDs)?

UCDs are a group of genetic conditions that prevent the body from removing waste nitrogen, leading to serious health issues.

What other products is Acer Therapeutics developing?

Acer is developing EDSIVO™ (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS) and has paused the development of ACER-801 (osanetant) for Vasomotor Symptoms (VMS).

Who supports OLPRUVA™ patients?

OLPRUVA™ patients are supported by Navigator by Acer Therapeutics, a dedicated patient support team that ensures seamless prescription management and patient care.

Has Acer regained rights to OLPRUVA™?

Yes, Acer has regained worldwide rights to OLPRUVA™ (excluding Geographical Europe) from Relief Therapeutics, allowing for reinvestment into potential expansion opportunities.

What are Acer's plans for OLPRUVA™ insurance coverage?

Acer is engaged in discussions with major pharmacy benefits managers and government payers to secure insurance coverage for OLPRUVA™, expected by the second half of 2023 for commercial plans and the third quarter of 2023 for Medicaid programs.

How is Acer supporting its OLPRUVA™ launch?

Acer has established its patient support program, Navigator by Acer Therapeutics, for efficient prescription management and patient support, and is actively engaging with payers for insurance coverage.

Where is Acer Therapeutics headquartered?

Acer Therapeutics Inc. is headquartered in Cambridge, MA, USA.

Acer Therapeutics Inc.

Nasdaq:ACER

ACER Rankings

ACER Stock Data

16.15M
18.37M
13.78%
29.91%
2.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newton